These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

555 related items for PubMed ID: 25587020

  • 1. Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis.
    Lehman DA, Baeten JM, McCoy CO, Weis JF, Peterson D, Mbara G, Donnell D, Thomas KK, Hendrix CW, Marzinke MA, Frenkel L, Ndase P, Mugo NR, Celum C, Overbaugh J, Matsen FA, Partners PrEP Study Team.
    J Infect Dis; 2015 Apr 15; 211(8):1211-8. PubMed ID: 25587020
    [Abstract] [Full Text] [Related]

  • 2. HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial.
    Liegler T, Abdel-Mohsen M, Bentley LG, Atchison R, Schmidt T, Javier J, Mehrotra M, Eden C, Glidden DV, McMahan V, Anderson PL, Li P, Wong JK, Buchbinder S, Guanira JV, Grant RM, iPrEx Study Team.
    J Infect Dis; 2014 Oct 15; 210(8):1217-27. PubMed ID: 24740633
    [Abstract] [Full Text] [Related]

  • 3. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial.
    Mugo NR, Hong T, Celum C, Donnell D, Bukusi EA, John-Stewart G, Wangisi J, Were E, Heffron R, Matthews LT, Morrison S, Ngure K, Baeten JM, Partners PrEP Study Team.
    JAMA; 2014 Oct 15; 312(4):362-71. PubMed ID: 25038355
    [Abstract] [Full Text] [Related]

  • 4. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.
    Celum C, Morrow RA, Donnell D, Hong T, Hendrix CW, Thomas KK, Fife KH, Nakku-Joloba E, Mujugira A, Baeten JM, Partners PrEP Study Team.
    Ann Intern Med; 2014 Jul 01; 161(1):11-9. PubMed ID: 24979446
    [Abstract] [Full Text] [Related]

  • 5. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
    Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, Henderson FL, Pathak SR, Soud FA, Chillag KL, Mutanhaurwa R, Chirwa LI, Kasonde M, Abebe D, Buliva E, Gvetadze RJ, Johnson S, Sukalac T, Thomas VT, Hart C, Johnson JA, Malotte CK, Hendrix CW, Brooks JT, TDF2 Study Group.
    N Engl J Med; 2012 Aug 02; 367(5):423-34. PubMed ID: 22784038
    [Abstract] [Full Text] [Related]

  • 6. Preexposure prophylaxis for HIV infection among African women.
    Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, Malahleha M, Owino F, Manongi R, Onyango J, Temu L, Monedi MC, Mak'Oketch P, Makanda M, Reblin I, Makatu SE, Saylor L, Kiernan H, Kirkendale S, Wong C, Grant R, Kashuba A, Nanda K, Mandala J, Fransen K, Deese J, Crucitti T, Mastro TD, Taylor D, FEM-PrEP Study Group.
    N Engl J Med; 2012 Aug 02; 367(5):411-22. PubMed ID: 22784040
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.
    Mugwanya KK, Wyatt C, Celum C, Donnell D, Mugo NR, Tappero J, Kiarie J, Ronald A, Baeten JM, Partners PrEP Study Team.
    JAMA Intern Med; 2015 Feb 02; 175(2):246-54. PubMed ID: 25531343
    [Abstract] [Full Text] [Related]

  • 9. Preexposure prophylaxis-selected drug resistance decays rapidly after drug cessation.
    Weis JF, Baeten JM, McCoy CO, Warth C, Donnell D, Thomas KK, Hendrix CW, Marzinke MA, Mugo N, Matsen FA, Celum C, Lehman DA, Partners PrEP Study Team.
    AIDS; 2016 Jan 02; 30(1):31-5. PubMed ID: 26731753
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.
    Baeten JM, Donnell D, Mugo NR, Ndase P, Thomas KK, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kidoguchi L, Coombs RW, Hendrix C, Marzinke MA, Frenkel L, Haberer JE, Bangsberg D, Celum C, Partners PrEP Study Team.
    Lancet Infect Dis; 2014 Nov 02; 14(11):1055-1064. PubMed ID: 25300863
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.
    Pozniak AL, Gallant JE, DeJesus E, Arribas JR, Gazzard B, Campo RE, Chen SS, McColl D, Enejosa J, Toole JJ, Cheng AK.
    J Acquir Immune Defic Syndr; 2006 Dec 15; 43(5):535-40. PubMed ID: 17057609
    [Abstract] [Full Text] [Related]

  • 15. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention.
    Donnell D, Baeten JM, Bumpus NN, Brantley J, Bangsberg DR, Haberer JE, Mujugira A, Mugo N, Ndase P, Hendrix C, Celum C.
    J Acquir Immune Defic Syndr; 2014 Jul 01; 66(3):340-8. PubMed ID: 24784763
    [Abstract] [Full Text] [Related]

  • 16. Characterization of HIV Seroconverters in a TDF/FTC PrEP Study: HPTN 067/ADAPT.
    Sivay MV, Li M, Piwowar-Manning E, Zhang Y, Hudelson SE, Marzinke MA, Amico RK, Redd A, Hendrix CW, Anderson PL, Bokoch K, Bekker LG, van Griensven F, Mannheimer S, Hughes JP, Grant R, Eshleman SH, HPTN 067/ADAPT Study Team.
    J Acquir Immune Defic Syndr; 2017 Jul 01; 75(3):271-279. PubMed ID: 28328548
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Tenofovir-based preexposure prophylaxis for HIV infection among African women.
    Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, Palanee T, Nakabiito C, van der Straten A, Noguchi L, Hendrix CW, Dai JY, Ganesh S, Mkhize B, Taljaard M, Parikh UM, Piper J, Mâsse B, Grossman C, Rooney J, Schwartz JL, Watts H, Marzinke MA, Hillier SL, McGowan IM, Chirenje ZM, VOICE Study Team.
    N Engl J Med; 2015 Feb 05; 372(6):509-18. PubMed ID: 25651245
    [Abstract] [Full Text] [Related]

  • 20. Study design considerations for evaluating efficacy of systemic preexposure prophylaxis interventions.
    Donnell D, Hughes JP, Wang L, Chen YQ, Fleming TR.
    J Acquir Immune Defic Syndr; 2013 Jul 05; 63 Suppl 2(0 2):S130-4. PubMed ID: 23764624
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.